Deutsch English Français

Contact

EP2387563

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP2387563

EP2387563 - MALATE SALT OF N- (4- { [ 6, 7-BIS (METHYLOXY) QUINOLIN-4-YL]OXY}PHENYL-N' - (4 -FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEREOF FOR THE TREATMENT OF CANCER [Right-click to bookmark this link]
Former [2011/47]	Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms therof for the treatment of cancer
	[2011/48]
Status	Patent maintained as amended Status updated on 25.03.2022 Database last updated on 20.07.2024
Most recent event Tooltip	25.03.2022	Patent maintained (B2 publication)	published on 27.04.2022 [2022/17]
Applicant(s)	For all designated states Exelixis, Inc. 210 East Grand Avenue P.O. Box 511 South San Francisco, CA 94080-0511 / US
	[2012/05]
Former [2012/02]	For all designated states Exelixis, Inc. P.O. Box 511 249 East Grand Avenue South San Francisco, CA 94080 / US
Former [2011/47]	For all designated states Exelixis, Inc. P.O. Box 511 249 East Grand Avenue South San Francisco, CA 94080 / US
	For all designated states Bristol-Myers Squibb Company P.O. Box 4000 Princeton, NJ 08543 / US
Inventor(s)	01 / BROWN, Adrian St. Clair 67 Stour Green Ely, Cambridgeshire CB6 2XJ / GB
	02 / LAMB, Peter 814 Mandana Blvd. Oakland CA 94610 / US
	03 / GALLAGHER, William, P. P.O. Box 4000 Princeton NJ 08543 / US
	[2011/47]
Representative(s)	Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
	[2022/17]
Former [2011/47]	Duckett, Anthony Joseph, et al Mathys & Squire LLP 120 Holborn London EC1N 2SQ / GB
Application number, filing date	10701175.1	15.01.2010
	[2022/17]
	WO2010US21194
Priority number, date	US20090145421P	16.01.2009 Original published format: US 145421 P
	[2011/47]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2010083414
	Date:	22.07.2010
	Language:	EN
	[2010/29]
	Type:	A1 Application with search report
	No.:	EP2387563
	Date:	23.11.2011
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 22.07.2010 takes the place of the publication of the European patent application.
	[2011/47]
	Type:	B1 Patent specification
	No.:	EP2387563
	Date:	06.03.2013
	Language:	EN
	[2013/10]
	Type:	B2 New European patent specification
	No.:	EP2387563
	Date:	27.04.2022
	Language:	EN
	[2022/17]
Search report(s)	International search report - published on:	EP	22.07.2010
Classification	IPC:	C07D215/227, A61K31/47, A61P35/00	[2011/47]
	CPC:	C07D215/22 (EP,CN,US); A61K31/47 (KR); C07D215/233 (EP,EA,US); A61P25/00 (EP); A61P35/00 (EP,KR); A61P43/00 (EP); (+) A61P5/14 (EP); C07B2200/13 (CN) (-)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2013/10]
Extension states	AL	12.08.2011
	BA	12.08.2011
	RS	12.08.2011
Title	German:	MALATSALZ VON N-(4-{[6,7-BIS(METHYLOXY)CHINOLIN-4-YL]OXY}PHENYL-N'-(4-FLUORPHENYL)CYCLOPROPAN-1,1-DICARBONSÄUREAMID UND KRISTALLINE FORMEN DAVON ZUR BEHANDLUNG VON KREBS	[2012/37]
	English:	MALATE SALT OF N- (4- { [ 6, 7-BIS (METHYLOXY) QUINOLIN-4-YL]OXY}PHENYL-N' - (4 -FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEREOF FOR THE TREATMENT OF CANCER	[2011/48]
	French:	SEL DE MALATE DE N-(4-{[6,7-BIS(MÉTHYLOXY)QUINOLIN-4-YL]OXY}PHÉNYL)-N'-(4-FLUOROPHÉNYL)CYCLOPROPANE-1,1-DICARBOXAMIDE ET FORMES CRISTALLINES DE CELUI-CI POUR LE TRAITEMENT DU CANCER	[2011/52]
	Former [2011/47]	MALATSALZ VON N-(4-{[6,7-BIS(METHYLOXY)CHINOLIN-4-YL]OXY}PHENYL-Ný-(4-FLUORPHENYL)CYCLOPROPAN-1-DICARBONSÄUREAMID UND KRISTALLINE FORMEN DAVON ZUR BEHANDLUNG VON KREBS
	Former [2011/47]	Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms therof for the treatment of cancer
	Former [2011/47]	Sel de malate de n-(4-{[6,7-bis(méthyloxy)quinolin-4-yl]oxy}phényl)-n'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide et formes cristallines de celui-ci pour le traitement du cancer
Entry into regional phase	12.08.2011	National basic fee paid
	12.08.2011	Designation fee(s) paid
	12.08.2011	Examination fee paid
Examination procedure	12.08.2011	Examination requested [2011/47]
	17.08.2012	Communication of intention to grant the patent
	13.12.2012	Fee for grant paid
	13.12.2012	Fee for publishing/printing paid
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 17.08.2012
Opposition(s)	Opponent(s)	01 05.12.2013 08.01.2014 ADMISSIBLE Gallafent, Alison Alison Gallafent Ltd 21 Bridge St Llandeilo SA19 6BN / GB Opponent's representative FRKelly Waterways House Grand Canal Quay Dublin D02 PD39 / IE
		02 05.12.2013 08.01.2014 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		03 06.12.2013 08.01.2014 ADMISSIBLE Ladendorf, Oliver Maiwald Patentanwalts -und Rechtsanwaltsgesellschaft mbH Elisenhof Elisenstraße 3 80335 München / DE Opponent's representative Ter Meer Steinmeister & Partner Patentanwälte mbB Nymphenburger Straße 4 80335 München / DE
		[N/P]
	Former [2019/46]
	Opponent(s)	01 05.12.2013 08.01.2014 ADMISSIBLE Gallafent, Alison Alison Gallafent Ltd 21 Bridge St Llandeilo SA19 6BN / GB Opponent's representative FRKelly 27 Clyde Road Dublin D04 F838 / IE
		02 05.12.2013 08.01.2014 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		03 06.12.2013 08.01.2014 ADMISSIBLE Ladendorf, Oliver Maiwald Patentanwalts -und Rechtsanwaltsgesellschaft mbH Elisenhof Elisenstraße 3 80335 München / DE Opponent's representative Ter Meer Steinmeister & Partner Patentanwälte mbB Nymphenburger Straße 4 80335 München / DE
	Former [2018/51]
	Opponent(s)	01 05.12.2013 08.01.2014 ADMISSIBLE Gallafent, Alison Alison Gallafent Ltd 21 Bridge St Llandeilo SA19 6BN / GB Opponent's representative FRKelly 27 Clyde Road Dublin D04 F838 / IE
		02 05.12.2013 08.01.2014 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Elkington & Fife LLP Prospect House 8 Pembroke Road Sevenoaks Kent TN13 1XR / GB
		03 06.12.2013 08.01.2014 ADMISSIBLE Ladendorf, Oliver Maiwald Patentanwalts -und Rechtsanwaltsgesellschaft mbH Elisenhof Elisenstraße 3 80335 ünchen / DE Opponent's representative Herzog, Fiesser & Partner Patentanwälte PartG mbB Isartorplatz 1 80331 München / DE
	Former [2017/36]
	Opponent(s)	01 05.12.2013 08.01.2014 ADMISSIBLE Gallafent, Alison Alison Gallafent Ltd 21 Bridge St Llandeilo SA19 6BN / GB Opponent's representative FRKelly 27 Clyde Road Dublin D04 F838 / IE
		02 05.12.2013 08.01.2014 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Cooke, Richard Spencer Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		03 06.12.2013 08.01.2014 ADMISSIBLE Ladendorf, Oliver Maiwald Patentanwalts GmbH Elisenhof Elisenstrasse 3 80355 Munich / DE Opponent's representative Herzog, Fiesser & Partner Patentanwälte PartG mbB Isartorplatz 1 80331 München / DE
	Former [2016/41]
	Opponent(s)	01 05.12.2013 08.01.2014 ADMISSIBLE Gallafent, Alison Alison Gallafent Ltd 21 Bridge St Llandeilo SA19 6BN / GB Opponent's representative O'Connell, Maura FRKelly 27 Clyde Road Dublin D04 F838 / IE
		02 05.12.2013 08.01.2014 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Cooke, Richard Spencer Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		03 06.12.2013 08.01.2014 ADMISSIBLE Ladendorf, Oliver Maiwald Patentanwalts GmbH Elisenhof Elisenstrasse 3 80355 Munich / DE Opponent's representative Herzog, Fiesser & Partner Patentanwälte PartG mbB Isartorplatz 1 80331 München / DE
	Former [2016/19]
	Opponent(s)	01 05.12.2013 08.01.2014 ADMISSIBLE Gallafent, Alison Alison Gallafent Ltd 21 Bridge St Llandeilo SA19 6BN / GB Opponent's representative O'Connell, Maura FRKelly 27 Clyde Road Ballsbridge Dublin 4 / IE
		02 05.12.2013 08.01.2014 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Cooke, Richard Spencer Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		03 06.12.2013 08.01.2014 ADMISSIBLE Ladendorf, Oliver Maiwald Patentanwalts GmbH Elisenhof Elisenstrasse 3 80355 Munich / DE Opponent's representative Altmann, Andreas, et al, et al Herzog Fiesser & Partner Patentanwälte PartG mbB Isartorplatz 1 80331 München / DE
	Former [2016/15]
	Opponent(s)	01 05.12.2013 08.01.2014 ADMISSIBLE Gallafent, Alison Alison Gallafent Ltd 21 Bridge St Llandeilo SA19 6BN / GB Opponent's representative O'Connell, Maura FRKelly 27 Clyde Road Ballsbridge Dublin 4 / IE
		02 05.12.2013 08.01.2014 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Cooke, Richard Spencer Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		03 06.12.2013 08.01.2014 ADMISSIBLE Ladendorf, Oliver Maiwald Patentanwalts GmbH Elisenhof Elisenstrasse 3 80355 Munich / DE Opponent's representative Ladendorf, Oliver, et al, et al Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE
	Former [2015/41]
	Opponent(s)	01 05.12.2013 08.01.2014 ADMISSIBLE Gallafent, Alison Alison Gallafent Ltd 21 Bridge St Llandeilo SA19 6BN / GB Opponent's representative Gallafent, Alison Alison Gallafent Ltd 21 Bridge St Llandeilo SA19 6BN / GB
		02 05.12.2013 08.01.2014 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Cooke, Richard Spencer Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		03 06.12.2013 08.01.2014 ADMISSIBLE Ladendorf, Oliver Maiwald Patentanwalts GmbH Elisenhof Elisenstrasse 3 80355 Munich / DE Opponent's representative Ladendorf, Oliver, et al, et al Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE
	Former [2014/25]
	Opponent(s)	01 05.12.2013 08.01.2014 ADMISSIBLE Gallafent, Alison Alison Gallafent Ltd 4 George Street Llandeilo Dyfed SA19 6AS / GB Opponent's representative Gallafent, Alison Alison Gallafent Ltd 4 George Street Llandeilo, South Wales SA19 6AS / GB
		02 05.12.2013 08.01.2014 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Cooke, Richard Spencer Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		03 06.12.2013 08.01.2014 ADMISSIBLE Ladendorf, Oliver Maiwald Patentanwalts GmbH Elisenhof Elisenstrasse 3 80355 Munich / DE Opponent's representative Ladendorf, Oliver, et al, et al Kraus & Weisert Thomas-Wimmer-Ring 15 80539 München / DE
	Former [2014/03]
	Opponent(s)	01 05.12.2013 Gallafent, Alison Alison Gallafent Ltd 4 George Street Llandeilo Dyfed SA19 6AS / GB Opponent's representative Gallafent, Alison Alison Gallafent Ltd 4 George Street Llandeilo, South Wales SA19 6AS / GB
		02 05.12.2013 Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Cooke, Richard Spencer Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		03 06.12.2013 Ladendorf, Oliver Maiwald Patentanwalts GmbH Elisenhof Elisenstrasse 3 80355 Munich / DE Opponent's representative Ladendorf, Oliver, et al, et al Maiwald Patentanwalts GmbH Elisenhof Elisenstraße 3 80335 München / DE
	13.01.2014	Invitation to proprietor to file observations on the notice of opposition
	22.09.2014	Reply of patent proprietor to notice(s) of opposition
	18.06.2015	Cancellation of oral proceeding that was planned for 19.01.2016
	14.12.2015	Date of oral proceedings
	07.01.2016	Despatch of interlocutory decision in opposition
	07.01.2016	Despatch of minutes of oral proceedings
	19.01.2016	Date of oral proceedings
	30.09.2021	Legal effect of interlocutory decision in opposition
	21.12.2021	Despatch of communication that the patent will be maintained as amended
	21.03.2022	Fee for printing new specification paid
Appeal following opposition	17.03.2016	Appeal received No. T0500/16
	17.05.2016	Statement of grounds filed
	30.09.2021	Result of appeal procedure: appeal of the opponent was rejected
	20.12.2021	Despatch of the decision of the Board of Appeal
	23.02.2016	Appeal received No. T0500/16
	17.05.2016	Statement of grounds filed
	30.09.2021	Result of appeal procedure: appeal of the opponent was rejected
	20.12.2021	Despatch of the decision of the Board of Appeal
	13.03.2015	Appeal received No. T0500/16
	17.03.2016	Statement of grounds filed
	30.09.2021	Result of appeal procedure: appeal of the opponent was rejected
	20.12.2021	Despatch of the decision of the Board of Appeal
	30.09.2021	Date of oral proceedings
Fees paid	Renewal fee
	11.01.2012	Renewal fee patent year 03
	10.01.2013	Renewal fee patent year 04
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[AD]WO2005030140 (EXELIXIS INC [US], et al) [AD] 1-15 * page 212, paragraph 353 - page 213; example 48 * * claims 1-168 ** page 159, paragraph 236 *
	by applicant	WO2005030140
		WO2008083319
		- PLOWMAN ET AL., DN&P, (1994), vol. 7, no. 6, pages 334 - 339
		- MAULIK ET AL., CYTOKINE & GROWTH FACTOR REVIEWS, (2002), vol. 13, pages 41 - 59
		- MATTER A., DRUG DISC. TECHNOL., (2001), vol. 6, pages 1005 - 1024
		- GOODMAN; GILMAN'S, The Pharmacological Basis of Therapeutics, MCGRAW-HILL PRESS, (2001), pages 155 - 173
		- J.W. MULLIN; J. NYVLT, "Programmed Cooling Batch Crystallizers", CHEMICAL ENGINEERING SCIENCE, (1971), vol. 26, page 3690377
		- OTWINOWSKI, Z.; MINOR, W., Macromolecular Crystallography, ACADEMIC, (1997), vol. 276, pages 307 - 326
		- J. COSIER; A.M. GLAZER, "Oxford Cryosystems Cryostream cooler", J. APPL. CRYST., (1986), vol. 19, page 105
		- International Tables for Crystallography, KYNOCH PRESS, (1974), vol. IV
		- YIN. S.; SCARINGE, R. P.; DIMARCO, J.; GALELLA, M.; GOUGOUTAS, J. Z., AMERICAN PHARMACEUTICAL REVIEW, (2003), vol. 6,2, page 80
		- A.E. BENNETT ET AL., J. CHEM. PHYS., (1995), vol. 103, page 6951
		- G. METZ; X. WU; S.O. SMITH, J. MAGN. RESON. A, (1994), vol. 110, pages 219 - 227
		- W.L. EARL; D.L. VANDERHART, J. MAGN. RESON., (1982), vol. 48, pages 35 - 54

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p